Seminars in Oncology
Volume 33, Issue 5 , Pages 544-551 , October 2006

Genetic Basis of Cancer of the Kidney

  • Sunil Sudarshan
    • ,
  • W. Marston Linehan

      Affiliations

    • Corresponding Author InformationAddress correspondence to W. Marston Linehan, MD, Urologic Oncology Branch, National Cancer Institute, 10 Center Dr, MSC 1107, Building 10 CRC Room 1-5940, Bethesda, MD 20892-1107.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056
  3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042
  4. Lonser R, Glenn G, Walther MM, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–2067
  5. McKusick VA. In: Mendelian Inheritance in Man. Baltimore, MD: Johns Hopkins Press; 1883;p. 534–535
  6. Walther MM, Enquist EG, Jennings SB, et al. Molecular genetics of renal cell carcinoma. In:  Vogelzang NJ,  Shipley WU,  Scardino P, et al. editor. Comprehensive Textbook of Genitourinary Oncology. (ed 2).. Philadelphia, PA: Williams & Wilkins; 1999;p. 116
  7. Glenn GM, Choyke PL, Zbar B, et al. Von Hippel-Lindau disease: Clinical review and molecular genetics. In:  Anderson EE editors. Problems in Urologic Surgery: Benign and Malignant Tumors of the Kidney. Philadelphia, PA: Lippincott; 1990;p. 312
  8. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–2172
  9. Walther MM, Lubensky IA, Venzon D, et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol. 1995;154:2010–2015
  10. Lamiell JM, Salazar FG, Hsia YE. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine. 1989;68:1–29
  11. Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301:592–595
  12. Pathak S, Strong LC, Ferrell RE, et al. Familial renal cell carcinoma with a 3:11 chromosome translocation limited to tumor cells. Science. 1982;217:939–941
  13. Kovacs G, Brusa P, de Riese W. Tissue-specific expression of a constitutional 3;6 translocation: Development of multiple bilateral renal-cell carcinomas. Int J Cancer. 1989;43:422–427
  14. Zbar B, Brauch H, Talmadge C, et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327:721–724
  15. Latif F, Tory K, Gnarra JR, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–1320
  16. Whaley JM, Naglich J, Gelbert L, et al. Germ-line mutations in the von Hipel-Lindau tumor-suppressor gene are similar to von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet. 1994;55:1092–1102
  17. Clinical Research Group for VHL in Japan. Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Hum Mol Genet. 1995;4:2233–2237
  18. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlation with phenotype. Hum Mutat. 1995;5:66–75
  19. Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994;3:1303–1308
  20. Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. J Med Genet. 1996;33:328–332
  21. Zbar B, Kishida T, Chen F, et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum Mutat. 1996;8:348–357
  22. Glavac D, Neumann HPH, Wittke C, et al. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet. 1997;98:271–280
  23. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12:417–423
  24. Lubensky IA, Gnarra JR, Bertheau P, et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol. 1996;149:2089–2094
  25. Gnarra JR, Tory K, Weng Y, et al. Mutation of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90
  26. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700–9704
  27. Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chrom Cancer. 1998;22:200–209
  28. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673–682
  29. Friedrich CA. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet. 2001;10:763–767
  30. Maranchie JK, Afonso A, Albert P, et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat. 2004;23:40–46
  31. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820–823
  32. Knudson AG, Strong LC. Mutation and cancer: Neuroblastoma and pheochromocytoma. Am J Hum Genet. 1972;24:514–532
  33. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 1995;269:1402–1406
  34. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A. 1997;94:2156–2161
  35. Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem. 2005;74:115–128
  36. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–472
  37. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292:464–468
  38. Pause A, Lee S, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A. 1998;95:993–998
  39. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A. 1996;93:10589–10594
  40. Mukhopadhyay D, Knebelmann B, Cohen HT, et al. The von Hippel-Lindau (VHL) tumor suppressor gene product interacts with Sp1 to repress vascular edothelial growth factor (VEGF) promoter activity. Mol Cell Biol. 1997;17:5629–5639
  41. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998;1:959–968
  42. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  43. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  44. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–624
  45. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561–566
  46. Zbar B, Glenn G, Lubensky IA, et al. Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol. 1995;153:907–912
  47. Ornstein DK, Lubensky IA, Venzon D, et al. Prevalence of microscopic tumors in normal appearing renal parenchyma from patients with hereditary papillary renal cancer. J Urol. 2000;163:431–433
  48. Kovacs G. Molecular cytogenetics of renal cell tumors. In:  Vande Woude G,  Klein G editor. Advances in Cancer Research. Frederick, MD: Academic Press; 1994;p. 1
  49. Schmidt L, Duh F-M, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73
  50. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282S–6289S
  51. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276:60–66
  52. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet. 1998;20:66–69
  53. Schmidt L, Junker K, Kinjerski T, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–2350
  54. Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: Germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. J Urol. 2004;172:1256–1261
  55. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977;113:1674–1677
  56. Toro J, Duray PH, Glenn GM, et al. Birt-Hogg-Dube syndrome: A novel marker of kidney neoplasia. Arch Dermatol. 1999;135:1195–1202
  57. Roth JS, Rabinowitz AD, Benson M, et al. Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol. 1993;29:1055–1056
  58. Schmidt LS, Warren MB, Nickerson ML, et al. Birt Hogg Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet. 2001;69:876–882
  59. Zbar B, Alvord G, Glenn G, et al. Risk of renal and colon neoplasms and spontaneous pneumothorax in the Birt Hogg Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:393–400
  60. Pavlovich CP, Hewitt S, Walther MM, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002;26:1542–1552
  61. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157–164
  62. Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD mutation spectrum and phenotype analysis in a large cohort of families with the Birt-Hogg-Dube syndrome. Am J Hum Genet. 2005;76:1023–1033
  63. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst. 2005;97:931–935
  64. Khoo SK, Giraud S, Kahnoski K, et al. Clinical and genetic studies of Birt-Hogg-Dube syndrome. J Med Genet. 2002;39:906–912
  65. Warren MB, Torres-Cabala CA, Turner ML, et al. Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues. Mod Pathol. 2004;17:998–1011
  66. Nagy A, Zoubakov D, Stupar Z, et al. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int J Cancer. 2004;109:472–475
  67. Bugert P, Gaul C, Weber K, et al. Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest. 1997;76:203–208
  68. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chrmosoomes 1,2,6,10,13,17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356–364
  69. Walther MM, Choyke PL, Glenn GM, et al. Renal cancer in families with hereditary renal cancer: Prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161:1475–1479
  70. Chernoff AM, Choyke PL, Linehan WM, et al. Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer. J Urol. 2001;165:1623–1624
  71. Herring JC, Enquist EG, Chernoff AC, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma—Ten year experience. J Urol. 2001;165:777–781
  72. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172:63–65
  73. Pavlovich CP, Grubb RL, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol. 2005;173:1482–1486
  74. Pavlovich CP, Walther MM, Choyke PL, et al. Percutaneous radiofrequency ablation of small renal tumors: Initial results. J Urol. 2002;167:10–15
  75. Hwang JJ, Walther MM, Pautler SE, et al. Radio frequency ablation of small renal tumors: Intermediate results. J Urol. 2004;171:1814–1818
  76. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95–106
  77. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol. 1973;53:409–416
  78. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98:3387–3382
  79. Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet. 2001;68:1264–1269
  80. Tomlinson IP, Alam NA, Rowan NA, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–410
  81. Wei M-H, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2005;43:18–27
  82. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–410
  83. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–851
  84. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268–270
  85. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49–54
  86. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet. 2004;74:153–159
  87. Isaacs JT, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallilic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143–153

 Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

PII: S0093-7754(06)00274-0

doi: 10.1053/j.seminoncol.2006.06.008

Seminars in Oncology
Volume 33, Issue 5 , Pages 544-551 , October 2006

Article Tools

* Image Usage & Resolution